Expertise in
7
conditions

Dr. Paul Chapman

Oncology
Cutaneous Oncology And Melanoma Program
1305 York Ave Fl 12, 
New York, NY 
Offers Telehealth
Expertise in
7
conditions
Cutaneous Oncology And Melanoma Program
1305 York Ave Fl 12, 
New York, NY 

Overview

Paul Chapman is an Oncologist practicing medicine in New York, New York.

Dr. Chapman is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Melanoma, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Uveal Melanoma, and Liver Embolization.

He is actively involved in clinical research, co-authoring 113 peer reviewed articles and participating in 6 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Cutaneous Oncology and Melanoma Program
1305 York Ave Fl 12, New York, NY 10021
Other Locations
Weill Cornell Medicine Hematology And Oncology
1305 York Ave, Fl 12, New York, NY 10021

Additional Areas of Focus

Dr. Chapman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Other, Drug
Study Drug: Vorinostat
Study Phase: Phase 2
Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated Melanoma
Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated Melanoma
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Phenformin
Study Phase: Phase 1
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Biological
Study Drug: CAB-ROR2-ADC
Study Phase: Phase 1/Phase 2
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
Why Do Patients Agree To or Decline Adjuvant Immunotherapy and Are They Satisfied With Their Decision?
Why Do Patients Agree To or Decline Adjuvant Immunotherapy and Are They Satisfied With Their Decision?
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Behavioral
A Phase I Open-Label Dose Escalation of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568)
A Phase I Open-Label Dose Escalation of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568)
Enrollment Status: Completed
Publish Date: January 22, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

113 Total Publications

Changing Role of Adjuvant Therapy in Stage III Melanoma.
Changing Role of Adjuvant Therapy in Stage III Melanoma.
Journal: The New England journal of medicine
Published: October 22, 2025
Similar Doctors
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.4 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (1.0 miles away)
929-343-3624
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Tap is an Oncologist practicing medicine in New York, New York. Dr. Tap is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization. Dr. Tap is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.4 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Frequently Asked Questions about Dr. Paul Chapman

How do I make an appointment with Dr. Paul Chapman?

You can book an appointment with Dr. Paul Chapman by calling their office at 914-229-2493. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul Chapman a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul Chapman is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul Chapman specialize in?

While Dr. Paul Chapman is a Oncology, they have specific expertise in Melanoma, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Paul Chapman participate in research or clinical trials?

Yes. Dr. Paul Chapman has published 113 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Paul Chapman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul Chapman accept my insurance?

Dr. Paul Chapman accepts most major insurance plans, including Aetna and Horizon Healthcare. We recommend calling the office directly at 914-229-2493 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chapman's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile